Vosseller Leigh 4
4 · TANDEM DIABETES CARE INC · Filed May 19, 2026
Research Summary
AI-generated summary of this filing
Tandem Diabetes (TNDM) CFO Leigh Vosseller Exercises Options, RSUs Vest
What Happened
Leigh Vosseller, Chief Financial Officer of Tandem Diabetes Care (TNDM), exercised/conversioned a total of 13,495 derivative shares on 2026-05-15 (three conversion events) and received 1,336 shares from an RSU award. To satisfy tax withholding on the RSU vesting, the company withheld 4,843 shares (three withholding events) generating approximately $62,087 in tax withholding proceeds. The RSU grant value reported for the 1,336 shares is $14,562 (at $10.90 per share).
Key Details
- Transaction date: 2026-05-15 (reported on Form 4 filed 2026-05-19). Filing appears within required business-day window.
- Derivative exercises/conversions (code M): 1,503 + 1,496 + 10,496 = 13,495 shares at $0.00 exercise price (acquired via conversion).
- Tax withholding (code F): 540, 537 and 3,766 shares withheld at $12.82 each, totaling $6,923; $6,884; and $48,280 (total ≈ $62,087). No open-market sale occurred—shares were withheld by the company to cover taxes (footnote F1).
- Grant/award (code A): 1,336 shares reported as acquired at $10.90 each (value $14,562). Footnotes indicate these are RSUs subject to the company's 2023 Long-Term Incentive Plan and that RSUs vest 33% on 5/15/2026 with the remainder vesting in equal quarterly installments thereafter (see F10, F4, F5).
- Shares owned after the transaction: not stated in this filing (not reported).
- Transaction codes: M = exercise/conversion of derivative, F = tax withholding, A = grant/award.
Context
This filing shows a typical combination of option/derivative conversion and RSU vesting with net settlement for tax withholding. The withheld shares satisfy tax obligations (not an open‑market sale), which is a routine administrative step and not necessarily a market sentiment signal. For retail investors, purchases or grants (like the RSU award) are generally more informative than routine tax-withholding disposals.
Insider Transaction Report
- Exercise/Conversion
Common Stock
2026-05-15+1,503→ 40,914 total - Tax Payment
Common Stock
[F1]2026-05-15$12.82/sh−540$6,923→ 40,374 total - Exercise/Conversion
Common Stock
2026-05-15+1,496→ 41,870 total - Tax Payment
Common Stock
[F1]2026-05-15$12.82/sh−537$6,884→ 41,333 total - Exercise/Conversion
Common Stock
2026-05-15+10,496→ 51,829 total - Tax Payment
Common Stock
[F1]2026-05-15$12.82/sh−3,766$48,280→ 48,063 total - Award
Common Stock
[F2]2026-05-15$10.90/sh+1,336$14,562→ 49,399 total - Exercise/Conversion
Restricted Stock Unit
[F4][F5][F6]2026-05-15−1,503→ 0 total→ Common Stock (1,503 underlying) - Exercise/Conversion
Restricted Stock Unit
[F7][F5][F8]2026-05-15−1,496→ 5,982 total→ Common Stock (1,496 underlying) - Exercise/Conversion
Restricted Stock Unit
[F9][F5][F10]2026-05-15−10,496→ 20,992 total→ Common Stock (10,496 underlying)
- 25,580(indirect: By Trust)
Common Stock
[F3]
Footnotes (10)
- [F1]Shares withheld by Tandem Diabetes Care Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold.
- [F10]RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2026, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.
- [F2]The reporting person is voluntarily reporting the acquisition of shares of common stock pursuant to the Tandem Diabetes Care, Inc. Amended and Restated 2013 Employee Stock Purchase Plan (ESPP), for the ESPP purchase period of November 18, 2025, through May 15, 2026. This transaction is also exempt under Rule 16b-3(c).
- [F3]The securities are held by the Leigh A. Vosseller Trust dated January 17, 2010, of which Leigh Vosseller is the Trustee.
- [F4]Awarded on May 25, 2023 pursuant to the Tandem Diabetes Care Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan).
- [F5]Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan.
- [F6]RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.
- [F7]Awarded on May 23, 2024 pursuant to the 2023 Plan.
- [F8]RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.
- [F9]Awarded on May 30, 2025 pursuant to the 2023 Plan.